theguardian : declared in Breast cancer drug rejected for NHS use on cost-benefit grounds
This was collected by Lucy William
follow all the new news about Drug
image uploaded by "theguardian" site
A breast cancer drug that costs £90,000 a year per patient has been turned down for use by the NHS on financial grounds, triggering an outcry from patients groups who say it prolongs the lives of people seriously ill with the disease.Kadcyla, made by Roche Pharmaceuticals, was rejected by the National Institute for Health and Care Excellence.It has the highest price tag ever for a cancer medicine and was turned down because its benefits did not justify its cost, Nice said.
about the details read more from here
image uploaded by "mirror" site
Get daily updates directly to your inbox + Subscribe Thank you for subscribing!Could not subscribe, try again later Invalid EmailThe NHS has been denied a pioneering breast cancer drug on cost grounds.Kadcyla costs £90,000 per course and The National Institute for Health and Care Excellence will rule today that that is "too high" to justify widespread use.
about the details read more from here
image uploaded by "telegraph" site
"Nice and Roche's inability to find a compromise is seeing secondary breast cancer patients left abandoned," she said."Responsibility lies on both sides, and such reckless brinkmanship is unfortunately about to rip away one of the best breast cancer drugs in years from patients in desperate need of a lifeline."Baroness Morgan urged the drug company to go further in the discount it was offering.But she also accused Nice of failing to do its job properly, by comparing the radical new drug with another very different treatment, which is not even available on the NHS.
about the details read more from here
We will quote to you the news of the best health sites Like : "theguardian" and the most famous medical experts : Sarah Boseley
daily : 2016-12-28 & on time : 19:38
follow all the new news about Drug
as mentioned in
Breast cancer drug rejected for NHS use on cost-benefit grounds
image uploaded by "theguardian" site
A breast cancer drug that costs £90,000 a year per patient has been turned down for use by the NHS on financial grounds, triggering an outcry from patients groups who say it prolongs the lives of people seriously ill with the disease.Kadcyla, made by Roche Pharmaceuticals, was rejected by the National Institute for Health and Care Excellence.It has the highest price tag ever for a cancer medicine and was turned down because its benefits did not justify its cost, Nice said.
about the details read more from here
Cancer drug snub for women dying of breast cancer as NHS denied it on cost grounds
image uploaded by "mirror" site
Get daily updates directly to your inbox + Subscribe Thank you for subscribing!Could not subscribe, try again later Invalid EmailThe NHS has been denied a pioneering breast cancer drug on cost grounds.Kadcyla costs £90,000 per course and The National Institute for Health and Care Excellence will rule today that that is "too high" to justify widespread use.
about the details read more from here
Breast cancer sufferers to be denied revolutionary life-extending drug due to cost
image uploaded by "telegraph" site
"Nice and Roche's inability to find a compromise is seeing secondary breast cancer patients left abandoned," she said."Responsibility lies on both sides, and such reckless brinkmanship is unfortunately about to rip away one of the best breast cancer drugs in years from patients in desperate need of a lifeline."Baroness Morgan urged the drug company to go further in the discount it was offering.But she also accused Nice of failing to do its job properly, by comparing the radical new drug with another very different treatment, which is not even available on the NHS.
about the details read more from here
Comments
Post a Comment